TY - JOUR T1 - Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer JF - Anticancer Research JO - Anticancer Res SP - 709 LP - 718 DO - 10.21873/anticanres.14001 VL - 40 IS - 2 AU - IOANNIS XOXAKOS AU - CONSTANTINA PETRAKI AU - PAUL MSAUEL AU - ATHANASIOS ARMAKOLAS AU - ALKIVIADIS GRIGORAKIS AU - STEFANOS STEFANAKIS AU - MICHAEL KOUTSILIERIS Y1 - 2020/02/01 UR - http://ar.iiarjournals.org/content/40/2/709.abstract N2 - Background/Aim: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. In contrast to localized disease, metastatic PCa leads to increased mortality. Kisspeptin (KISS1) functions as a metastasis suppressor in various cancers. The aim of this study was to detect the expression of KISS1 and its receptor GPR54 (KISS1R) in prostate cancer. Materials and Methods: The expression of KISS1 and KISS1R was examined in prostate cancer tissue specimens after radical prostatectomy. Results: A higher expression of KISS1 and KISS1R was shown in patients with localized tumors (Stage ≤IIb) compared to patients with advanced (Stage ≥III) tumor. High Gleason score PCa and higher prognostic groups patients showed a lower expression rate of both KISS1 and KISS1R. Conclusion: A down-regulation of KISS1-KISS1R system was detected in advanced prostate cancer. KISS1as tumor suppressor might be useful in the future for the diagnosis, risk assessment of prostate cancer progression, as well as a therapeutic target for aggressive tumors. ER -